$HCM News

Save the Date: HUTCHMED to Host Expert Insights Event on Recent Savolitinib Clinical Data in Non-Small Cell Lung Cancer

HUTCHMED Highlights SANOVO Phase III Data for ORPATHYS® plus TAGRISSO® in First-Line EGFR-Mutated Lung Cancer Presented at ESMO Congress 2026

HUTCHMED Highlights SANOVO Phase III Data At ESMO, ORPATHYS Plus TAGRISSO Cuts Progression Or Death Risk 44% In First-Line EGFR-Mutated Lung Cancer, Improves OS; China Supplemental NDA Planned

HUTCHMED Announced At ESMO Sunday, SAFFRON Phase III Shows ORPATHYS Plus TAGRISSO Cut Progression Or Death Risk 45%, Death Risk 32% Versus Chemotherapy In MET-Driven EGFR-Mutated Lung Cancer

HUTCHMED Highlights SAFFRON Global Phase III Data Presented at ESMO Congress 2026 and Simultaneously Published in The New England Journal of Medicine

What HUTCHMED (China) (AIM:HCM)'s GSK Licensing Deal Means For Shareholders

HUTCHMED (China) (AIM:HCM) Closes GSK Deal, Is The Stock Still 38% Undervalued?

HUTCHMED Announces Closing of KRAS-EGFR-Antibody Conjugate Therapy License to GSK Outside China

HUTCHMED (AIM:HCM) Stock Looks Expensive Relative To Current Earnings

HUTCHMED Announces Submission of US NDA for ORPATHYS® plus TAGRISSO® in MET-Driven EGFR-Mutated Lung Cancer

HUTCHMED Initiates Global Trial of KRAS-EGFR-Antibody Conjugate Therapy HMPL-A830 in Patients with Solid Tumors

GSK Bets on HUTCHMED to Expand its Multi-Billion-Dollar Oncology Opportunity

HUTCHMED Highlights Clinical Data to be Presented at the ESMO Congress 2026

HUTCHMED (China) Reports H1 2026 Results: Full Earnings Call Transcript

HUTCHMED (China) Limited (HCM) Discusses Strategic Partnership With GSK and Licensing of Oncology Asset A830 - Slideshow

HUTCHMED Lands GSK Deal Worth Up to $1.3B for KRAS-EGFR Cancer Therapy

HUTCHMED (China) Limited (HCM) Discusses Strategic Partnership With GSK and Licensing of Oncology Asset A830 Transcript

Panmure and Cavendish reiterate buy on Hutchmed after GSK deal

HUTCHMED shares jump 17% on US$1.3 billion GSK cancer drug deal

HUTCHMED Signs GSK Cancer Drug Deal Worth Up To $1.3B, Gets $110M Upfront